ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
ABEONA THERAPEUTICS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.41−0.02 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $251.58M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.97 (−18.03%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ABEONA THERAPEUTICS INC. reported revenue of $25.52M for the twelve months to Jun 30, 2026. Free cash flow was -$81.53M.
Revenue
$25.52M
TTM Q2 2026
Operating income
-$83.62M
TTM Q2 2026
Free cash flow
-$81.53M
TTM Q2 2026
EPS, diluted
-$1.07
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $251.58M
- P/E ratio
- –
- Price to sales
- 9.86
- Price to book
- 1.96
- Dividend yield
- –
- Free cash flow yield
- -32.41%
Fundamentals
- Revenue
- $25.52M
- Net income
- -$62.89M
- EPS, diluted
- -$1.07
- Free cash flow
- -$81.53M
- Book value per share
- $2.24
- Diluted shares
- 57M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$25.52M
Gross profit
$17.12M
Operating income
-$83.62M
Net income
-$62.89M-209.9% YoY
EPS, diluted
-$1.07
Free cash flow
-$81.53M
Reported periodTrailing twelve months